The nuclear oncoprotein FOSL1 is overexpressed in most solid tumors including lung cancer [26], breast cancer [27], ovarian cancer [28], prostate cancer [29], gastric cancer [30], colorectal cancer (CRC) [31], head and neck squamous cell carcinomas [32], and GBM [33], and has emerged as a prominent therapeutic target [34]. The gene discussed is FOSL1; the disease is prostate cancer.